Todd Pitts
Concepts (373)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Colorectal Neoplasms | 22 | 2022 | 620 | 2.980 |
Why?
| Protein Kinase Inhibitors | 19 | 2020 | 788 | 2.030 |
Why?
| Xenograft Model Antitumor Assays | 37 | 2022 | 716 | 2.000 |
Why?
| Antineoplastic Agents | 25 | 2020 | 1890 | 1.580 |
Why?
| Azepines | 4 | 2020 | 67 | 1.450 |
Why?
| Pyrimidines | 9 | 2020 | 377 | 1.300 |
Why?
| Pyrazines | 6 | 2018 | 70 | 1.110 |
Why?
| Cell Line, Tumor | 33 | 2022 | 2756 | 1.040 |
Why?
| Mice, Nude | 24 | 2020 | 641 | 1.020 |
Why?
| Cell Proliferation | 21 | 2020 | 2197 | 0.900 |
Why?
| Fluorouracil | 1 | 2022 | 149 | 0.810 |
Why?
| Triple Negative Breast Neoplasms | 6 | 2020 | 157 | 0.800 |
Why?
| Camptothecin | 5 | 2022 | 98 | 0.680 |
Why?
| Apoptosis | 20 | 2022 | 2363 | 0.670 |
Why?
| Imidazoles | 4 | 2018 | 209 | 0.670 |
Why?
| Aurora Kinase A | 4 | 2020 | 50 | 0.670 |
Why?
| Proto-Oncogene Proteins | 5 | 2018 | 604 | 0.670 |
Why?
| Drug Resistance, Neoplasm | 11 | 2020 | 646 | 0.610 |
Why?
| Drug Synergism | 4 | 2014 | 314 | 0.600 |
Why?
| Neoplasms | 9 | 2022 | 2110 | 0.580 |
Why?
| Cell Cycle Proteins | 2 | 2018 | 559 | 0.530 |
Why?
| Cell Cycle Checkpoints | 3 | 2019 | 84 | 0.520 |
Why?
| Hydroxamic Acids | 3 | 2011 | 80 | 0.520 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2020 | 1359 | 0.510 |
Why?
| Tumor Microenvironment | 5 | 2022 | 440 | 0.500 |
Why?
| Histone Deacetylase Inhibitors | 4 | 2022 | 199 | 0.500 |
Why?
| Receptor, IGF Type 1 | 3 | 2013 | 58 | 0.500 |
Why?
| Mice | 38 | 2022 | 15075 | 0.490 |
Why?
| Pyrazoles | 5 | 2018 | 361 | 0.490 |
Why?
| Disease Models, Animal | 10 | 2022 | 3565 | 0.480 |
Why?
| Adrenocortical Carcinoma | 3 | 2020 | 47 | 0.480 |
Why?
| Mitogen-Activated Protein Kinases | 3 | 2014 | 269 | 0.470 |
Why?
| Antimitotic Agents | 1 | 2013 | 8 | 0.470 |
Why?
| Benzimidazoles | 5 | 2018 | 135 | 0.460 |
Why?
| Pancreatic Neoplasms | 5 | 2020 | 716 | 0.440 |
Why?
| G2 Phase Cell Cycle Checkpoints | 4 | 2022 | 41 | 0.440 |
Why?
| TOR Serine-Threonine Kinases | 2 | 2018 | 358 | 0.440 |
Why?
| Cyclin-Dependent Kinases | 1 | 2013 | 111 | 0.430 |
Why?
| Boronic Acids | 2 | 2011 | 33 | 0.420 |
Why?
| Animals | 42 | 2022 | 32091 | 0.420 |
Why?
| Molecular Targeted Therapy | 2 | 2019 | 351 | 0.410 |
Why?
| Quinoxalines | 4 | 2020 | 61 | 0.400 |
Why?
| Colonic Neoplasms | 2 | 2013 | 221 | 0.370 |
Why?
| Biomarkers, Tumor | 6 | 2018 | 1045 | 0.370 |
Why?
| Drug Screening Assays, Antitumor | 5 | 2020 | 180 | 0.360 |
Why?
| Melanoma | 4 | 2018 | 653 | 0.360 |
Why?
| Signal Transduction | 17 | 2019 | 4537 | 0.360 |
Why?
| Heterografts | 3 | 2021 | 121 | 0.360 |
Why?
| Oxidoreductases Acting on CH-CH Group Donors | 2 | 2020 | 20 | 0.340 |
Why?
| Gene Expression Regulation, Neoplastic | 9 | 2020 | 1142 | 0.330 |
Why?
| Wnt Signaling Pathway | 4 | 2020 | 149 | 0.320 |
Why?
| Adrenal Cortex Neoplasms | 2 | 2020 | 48 | 0.320 |
Why?
| Gene Expression Profiling | 6 | 2016 | 1567 | 0.310 |
Why?
| Cell Cycle | 7 | 2018 | 541 | 0.310 |
Why?
| Enzyme Inhibitors | 5 | 2020 | 749 | 0.300 |
Why?
| Ephrin-B2 | 2 | 2019 | 42 | 0.300 |
Why?
| Piperazines | 2 | 2020 | 314 | 0.300 |
Why?
| Programmed Cell Death 1 Receptor | 2 | 2020 | 195 | 0.300 |
Why?
| Deoxycytidine | 2 | 2020 | 136 | 0.300 |
Why?
| Humans | 60 | 2022 | 115297 | 0.300 |
Why?
| Drug Delivery Systems | 1 | 2010 | 301 | 0.290 |
Why?
| Tumor Suppressor Protein p53 | 4 | 2016 | 442 | 0.290 |
Why?
| Quinazolines | 3 | 2015 | 241 | 0.290 |
Why?
| Phosphatidylinositol 3-Kinases | 5 | 2018 | 329 | 0.280 |
Why?
| Anilides | 2 | 2018 | 67 | 0.270 |
Why?
| Oncogene Proteins, Fusion | 2 | 2018 | 177 | 0.270 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 3 | 2019 | 113 | 0.270 |
Why?
| Mutation | 9 | 2018 | 3371 | 0.270 |
Why?
| Female | 38 | 2020 | 59773 | 0.270 |
Why?
| Gene Dosage | 4 | 2015 | 127 | 0.260 |
Why?
| Cyclosporine | 2 | 2018 | 169 | 0.260 |
Why?
| Lymphocytes, Tumor-Infiltrating | 3 | 2020 | 110 | 0.260 |
Why?
| Immunoblotting | 6 | 2015 | 284 | 0.250 |
Why?
| Pyrimidinones | 2 | 2015 | 86 | 0.240 |
Why?
| Proto-Oncogene Proteins B-raf | 3 | 2018 | 191 | 0.240 |
Why?
| Proto-Oncogene Proteins p21(ras) | 6 | 2016 | 229 | 0.240 |
Why?
| Pyridones | 2 | 2015 | 122 | 0.240 |
Why?
| ras Proteins | 4 | 2013 | 137 | 0.230 |
Why?
| Receptor, Notch1 | 2 | 2015 | 59 | 0.230 |
Why?
| Neoplasm Transplantation | 4 | 2018 | 235 | 0.230 |
Why?
| Pyridines | 2 | 2018 | 417 | 0.220 |
Why?
| Immunotherapy | 3 | 2022 | 489 | 0.220 |
Why?
| Antineoplastic Agents, Immunological | 3 | 2020 | 158 | 0.220 |
Why?
| HCT116 Cells | 3 | 2018 | 69 | 0.210 |
Why?
| Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 61 | 0.210 |
Why?
| Drug Design | 2 | 2013 | 155 | 0.200 |
Why?
| beta Catenin | 2 | 2020 | 221 | 0.200 |
Why?
| Gene Knockdown Techniques | 4 | 2020 | 303 | 0.190 |
Why?
| DNA-Binding Proteins | 2 | 2020 | 1308 | 0.190 |
Why?
| Momordica charantia | 1 | 2020 | 14 | 0.180 |
Why?
| Benzoxazoles | 1 | 2020 | 16 | 0.180 |
Why?
| HT29 Cells | 2 | 2018 | 37 | 0.180 |
Why?
| Neoplasms, Experimental | 2 | 2019 | 153 | 0.180 |
Why?
| eIF-2 Kinase | 1 | 2019 | 24 | 0.170 |
Why?
| Immune System | 1 | 2021 | 174 | 0.170 |
Why?
| src-Family Kinases | 2 | 2017 | 88 | 0.170 |
Why?
| DNA Helicases | 1 | 2020 | 131 | 0.170 |
Why?
| Inhibitory Concentration 50 | 2 | 2016 | 78 | 0.170 |
Why?
| Tumor Burden | 2 | 2018 | 267 | 0.160 |
Why?
| Receptor, EphB4 | 1 | 2019 | 29 | 0.160 |
Why?
| Plant Extracts | 1 | 2020 | 153 | 0.160 |
Why?
| Breast Neoplasms, Male | 1 | 2018 | 28 | 0.160 |
Why?
| Coenzymes | 1 | 2018 | 16 | 0.160 |
Why?
| 4-Aminobenzoic Acid | 1 | 2018 | 6 | 0.160 |
Why?
| Thermodynamics | 1 | 2020 | 378 | 0.160 |
Why?
| MAP Kinase Kinase Kinases | 2 | 2015 | 67 | 0.160 |
Why?
| Neoplasm Invasiveness | 3 | 2020 | 446 | 0.160 |
Why?
| Septins | 1 | 2018 | 40 | 0.150 |
Why?
| Oncogene Proteins v-abl | 1 | 2017 | 4 | 0.150 |
Why?
| Adrenal Cortex | 1 | 2018 | 32 | 0.150 |
Why?
| Carcinoma, Pancreatic Ductal | 1 | 2020 | 210 | 0.150 |
Why?
| Dasatinib | 1 | 2017 | 45 | 0.150 |
Why?
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 31 | 0.150 |
Why?
| Angiogenesis Inhibitors | 3 | 2018 | 213 | 0.140 |
Why?
| Neoplasm Proteins | 1 | 2020 | 387 | 0.140 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2014 | 86 | 0.140 |
Why?
| Ubiquitin-Activating Enzymes | 1 | 2016 | 13 | 0.140 |
Why?
| Cyclopentanes | 1 | 2016 | 15 | 0.140 |
Why?
| Corynebacterium | 1 | 2017 | 36 | 0.140 |
Why?
| Tumor Cells, Cultured | 4 | 2020 | 840 | 0.140 |
Why?
| Transplantation, Heterologous | 4 | 2022 | 187 | 0.140 |
Why?
| Corynebacterium Infections | 1 | 2017 | 31 | 0.140 |
Why?
| Insulin-Like Growth Factor I | 1 | 2018 | 285 | 0.140 |
Why?
| Tankyrases | 1 | 2016 | 12 | 0.140 |
Why?
| Autophagy | 1 | 2018 | 236 | 0.130 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 107 | 0.130 |
Why?
| Cetuximab | 1 | 2016 | 96 | 0.130 |
Why?
| Biliary Tract Neoplasms | 1 | 2015 | 20 | 0.130 |
Why?
| Capecitabine | 1 | 2015 | 46 | 0.130 |
Why?
| Amyloid Precursor Protein Secretases | 2 | 2013 | 73 | 0.130 |
Why?
| Adenocarcinoma | 2 | 2020 | 790 | 0.130 |
Why?
| Drug Discovery | 1 | 2016 | 124 | 0.130 |
Why?
| Genes, ras | 2 | 2018 | 91 | 0.130 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 663 | 0.130 |
Why?
| Cell Survival | 3 | 2019 | 1011 | 0.130 |
Why?
| Diphenylamine | 1 | 2014 | 6 | 0.130 |
Why?
| Germ-Line Mutation | 2 | 2018 | 132 | 0.120 |
Why?
| DNA Copy Number Variations | 1 | 2015 | 156 | 0.120 |
Why?
| Piperidines | 1 | 2015 | 164 | 0.120 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2014 | 67 | 0.120 |
Why?
| Benzamides | 1 | 2014 | 170 | 0.120 |
Why?
| Urinary Bladder Neoplasms | 1 | 2016 | 198 | 0.120 |
Why?
| Protein Kinases | 1 | 2015 | 300 | 0.110 |
Why?
| Up-Regulation | 1 | 2016 | 818 | 0.110 |
Why?
| Receptor, Insulin | 1 | 2013 | 93 | 0.110 |
Why?
| Tetrahydronaphthalenes | 1 | 2013 | 29 | 0.110 |
Why?
| Valine | 1 | 2013 | 74 | 0.110 |
Why?
| Mitosis | 1 | 2013 | 167 | 0.110 |
Why?
| Receptors, Notch | 1 | 2013 | 84 | 0.110 |
Why?
| Tumor Suppressor Proteins | 1 | 2015 | 282 | 0.110 |
Why?
| Bortezomib | 2 | 2011 | 41 | 0.110 |
Why?
| Computational Biology | 1 | 2015 | 525 | 0.100 |
Why?
| Middle Aged | 12 | 2020 | 26936 | 0.100 |
Why?
| Sirolimus | 1 | 2013 | 191 | 0.100 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2013 | 180 | 0.100 |
Why?
| 3' Untranslated Regions | 1 | 2012 | 139 | 0.100 |
Why?
| Head and Neck Neoplasms | 1 | 2016 | 460 | 0.100 |
Why?
| Benzodioxoles | 1 | 2012 | 83 | 0.100 |
Why?
| Proteasome Inhibitors | 1 | 2011 | 40 | 0.100 |
Why?
| Carcinoma, Squamous Cell | 1 | 2016 | 596 | 0.100 |
Why?
| Aldehyde Dehydrogenase | 1 | 2012 | 130 | 0.100 |
Why?
| Neoplasm Metastasis | 3 | 2018 | 522 | 0.090 |
Why?
| Nuclear Proteins | 1 | 2015 | 591 | 0.090 |
Why?
| Protease Inhibitors | 1 | 2011 | 100 | 0.090 |
Why?
| Phosphorylation | 4 | 2019 | 1569 | 0.090 |
Why?
| Mice, Inbred NOD | 2 | 2022 | 559 | 0.090 |
Why?
| Breast Neoplasms | 2 | 2012 | 1858 | 0.090 |
Why?
| Aged | 9 | 2020 | 19253 | 0.090 |
Why?
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2009 | 6 | 0.090 |
Why?
| Mice, Inbred BALB C | 3 | 2020 | 1164 | 0.080 |
Why?
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2009 | 67 | 0.080 |
Why?
| Carcinoma, Hepatocellular | 1 | 2011 | 223 | 0.080 |
Why?
| Gastrointestinal Neoplasms | 1 | 2009 | 60 | 0.080 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 3 | 2014 | 78 | 0.080 |
Why?
| Cell Movement | 2 | 2011 | 869 | 0.080 |
Why?
| Immunosuppressive Agents | 1 | 2013 | 663 | 0.080 |
Why?
| Proto-Oncogene Proteins c-akt | 3 | 2018 | 396 | 0.080 |
Why?
| Positron-Emission Tomography | 3 | 2018 | 292 | 0.080 |
Why?
| Prognosis | 4 | 2019 | 3337 | 0.080 |
Why?
| Neutrophils | 3 | 2019 | 1080 | 0.080 |
Why?
| Feasibility Studies | 1 | 2010 | 744 | 0.070 |
Why?
| Farnesyltranstransferase | 1 | 2007 | 20 | 0.070 |
Why?
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 757 | 0.070 |
Why?
| Protein Conformation | 2 | 2020 | 822 | 0.070 |
Why?
| Adult | 10 | 2018 | 30576 | 0.070 |
Why?
| Reproducibility of Results | 2 | 2010 | 2811 | 0.070 |
Why?
| Maximum Tolerated Dose | 2 | 2020 | 181 | 0.070 |
Why?
| Gene Expression | 2 | 2019 | 1451 | 0.070 |
Why?
| Quinolones | 1 | 2007 | 97 | 0.070 |
Why?
| Male | 12 | 2020 | 55796 | 0.070 |
Why?
| Neovascularization, Pathologic | 2 | 2018 | 281 | 0.060 |
Why?
| Models, Molecular | 2 | 2020 | 1388 | 0.060 |
Why?
| Structure-Activity Relationship | 2 | 2018 | 507 | 0.060 |
Why?
| HMGB1 Protein | 1 | 2003 | 46 | 0.050 |
Why?
| Magnetic Resonance Spectroscopy | 2 | 2018 | 482 | 0.050 |
Why?
| Proto-Oncogene Proteins c-raf | 1 | 2002 | 43 | 0.050 |
Why?
| Adrenergic alpha-Agonists | 1 | 2002 | 29 | 0.050 |
Why?
| Adrenergic alpha-Antagonists | 1 | 2002 | 30 | 0.050 |
Why?
| Histones | 2 | 2022 | 535 | 0.050 |
Why?
| Neuroimmunomodulation | 1 | 2002 | 69 | 0.050 |
Why?
| Histone Deacetylase 1 | 1 | 2022 | 16 | 0.050 |
Why?
| Aurora Kinases | 2 | 2012 | 28 | 0.050 |
Why?
| Adrenergic beta-Agonists | 1 | 2002 | 127 | 0.050 |
Why?
| Endotoxemia | 1 | 2002 | 84 | 0.050 |
Why?
| Flow Cytometry | 2 | 2019 | 1045 | 0.050 |
Why?
| Genetic Predisposition to Disease | 1 | 2010 | 2202 | 0.050 |
Why?
| Caspase 3 | 2 | 2013 | 234 | 0.050 |
Why?
| Acetylation | 1 | 2022 | 212 | 0.050 |
Why?
| Chimerism | 1 | 2021 | 28 | 0.050 |
Why?
| Campylobacter jejuni | 1 | 2000 | 11 | 0.050 |
Why?
| Lymphoid Tissue | 1 | 2021 | 63 | 0.050 |
Why?
| Lymphocyte Subsets | 1 | 2021 | 77 | 0.050 |
Why?
| Cluster Analysis | 2 | 2012 | 469 | 0.050 |
Why?
| Catalase | 1 | 2000 | 118 | 0.050 |
Why?
| TCF Transcription Factors | 1 | 2020 | 21 | 0.050 |
Why?
| Adrenergic beta-Antagonists | 1 | 2002 | 292 | 0.050 |
Why?
| Mice, SCID | 1 | 2021 | 321 | 0.050 |
Why?
| Histone Deacetylases | 1 | 2022 | 196 | 0.050 |
Why?
| RNA, Neoplasm | 1 | 2020 | 76 | 0.040 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2020 | 82 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 57 | 0.040 |
Why?
| Indolizines | 1 | 2019 | 3 | 0.040 |
Why?
| Forkhead Box Protein M1 | 1 | 2019 | 6 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 99 | 0.040 |
Why?
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2019 | 22 | 0.040 |
Why?
| Organoids | 1 | 2020 | 75 | 0.040 |
Why?
| Small Molecule Libraries | 1 | 2020 | 81 | 0.040 |
Why?
| MAP Kinase Kinase 2 | 2 | 2013 | 27 | 0.040 |
Why?
| Crystallography, X-Ray | 1 | 2020 | 408 | 0.040 |
Why?
| MAP Kinase Kinase 1 | 2 | 2013 | 67 | 0.040 |
Why?
| High-Throughput Screening Assays | 1 | 2020 | 123 | 0.040 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2018 | 23 | 0.040 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2020 | 169 | 0.040 |
Why?
| Genetic Linkage | 1 | 1999 | 311 | 0.040 |
Why?
| Flavin-Adenine Dinucleotide | 1 | 2018 | 14 | 0.040 |
Why?
| NADP | 1 | 2018 | 41 | 0.040 |
Why?
| Hemorrhage | 1 | 2002 | 598 | 0.040 |
Why?
| Nausea | 1 | 2018 | 102 | 0.040 |
Why?
| Multifactorial Inheritance | 1 | 1999 | 140 | 0.040 |
Why?
| Carcinogenesis | 1 | 2019 | 180 | 0.040 |
Why?
| Aldosterone | 1 | 2018 | 42 | 0.040 |
Why?
| Radiotherapy | 1 | 2019 | 185 | 0.040 |
Why?
| Breast | 1 | 2018 | 129 | 0.040 |
Why?
| DNA Damage | 1 | 2020 | 348 | 0.040 |
Why?
| Kaplan-Meier Estimate | 1 | 2020 | 825 | 0.040 |
Why?
| Area Under Curve | 1 | 2018 | 277 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2020 | 958 | 0.040 |
Why?
| Catalytic Domain | 1 | 2018 | 202 | 0.040 |
Why?
| Diarrhea | 1 | 2018 | 173 | 0.040 |
Why?
| RNA, Small Interfering | 1 | 2019 | 546 | 0.040 |
Why?
| Autistic Disorder | 1 | 1999 | 163 | 0.040 |
Why?
| Hypertension | 2 | 2018 | 1063 | 0.040 |
Why?
| Recombinant Proteins | 1 | 2020 | 1241 | 0.040 |
Why?
| Disease-Free Survival | 1 | 2018 | 625 | 0.040 |
Why?
| Fatigue | 1 | 2018 | 293 | 0.030 |
Why?
| RNA, Messenger | 2 | 2020 | 2579 | 0.030 |
Why?
| Ubiquitination | 1 | 2016 | 86 | 0.030 |
Why?
| Axin Protein | 1 | 2016 | 17 | 0.030 |
Why?
| Protein Isoforms | 1 | 2017 | 337 | 0.030 |
Why?
| Sequence Analysis, RNA | 1 | 2018 | 396 | 0.030 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2019 | 347 | 0.030 |
Why?
| Administration, Oral | 1 | 2018 | 735 | 0.030 |
Why?
| Algorithms | 2 | 2015 | 1488 | 0.030 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 519 | 0.030 |
Why?
| Jagged-1 Protein | 1 | 2015 | 22 | 0.030 |
Why?
| Serrate-Jagged Proteins | 1 | 2015 | 27 | 0.030 |
Why?
| Tumor Protein p73 | 1 | 2015 | 15 | 0.030 |
Why?
| Gene Duplication | 1 | 2015 | 61 | 0.030 |
Why?
| Binding Sites | 1 | 2018 | 1187 | 0.030 |
Why?
| Immunohistochemistry | 1 | 2019 | 1634 | 0.030 |
Why?
| Databases, Genetic | 1 | 2015 | 199 | 0.030 |
Why?
| Biopsy | 1 | 2018 | 1053 | 0.030 |
Why?
| Mice, Knockout | 1 | 2021 | 2607 | 0.030 |
Why?
| Treatment Outcome | 3 | 2015 | 9127 | 0.030 |
Why?
| Transcription, Genetic | 1 | 2020 | 1311 | 0.030 |
Why?
| Calcium-Binding Proteins | 1 | 2015 | 205 | 0.030 |
Why?
| Caspase 7 | 1 | 2013 | 22 | 0.030 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2019 | 687 | 0.030 |
Why?
| Butadienes | 1 | 2013 | 32 | 0.030 |
Why?
| Cell Growth Processes | 1 | 2013 | 51 | 0.030 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2015 | 347 | 0.030 |
Why?
| Survival Analysis | 1 | 2016 | 1218 | 0.030 |
Why?
| Phenotype | 1 | 2021 | 2854 | 0.030 |
Why?
| Tumor Stem Cell Assay | 1 | 2012 | 34 | 0.030 |
Why?
| Everolimus | 1 | 2013 | 63 | 0.030 |
Why?
| Nitriles | 1 | 2013 | 154 | 0.030 |
Why?
| Random Allocation | 1 | 2013 | 331 | 0.030 |
Why?
| Neoplasm Staging | 1 | 2015 | 1190 | 0.030 |
Why?
| p38 Mitogen-Activated Protein Kinases | 2 | 2003 | 252 | 0.030 |
Why?
| Immunoprecipitation | 1 | 2012 | 156 | 0.030 |
Why?
| Calcium Signaling | 1 | 2013 | 211 | 0.020 |
Why?
| Cellular Senescence | 1 | 2012 | 150 | 0.020 |
Why?
| Disease Progression | 1 | 2018 | 2423 | 0.020 |
Why?
| Kinetics | 1 | 2014 | 1549 | 0.020 |
Why?
| PTEN Phosphohydrolase | 1 | 2012 | 138 | 0.020 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2012 | 305 | 0.020 |
Why?
| Enzyme Activation | 2 | 2003 | 776 | 0.020 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2011 | 137 | 0.020 |
Why?
| Receptor, ErbB-2 | 1 | 2012 | 300 | 0.020 |
Why?
| Li-Fraumeni Syndrome | 1 | 2010 | 11 | 0.020 |
Why?
| Neutropenia | 1 | 2010 | 127 | 0.020 |
Why?
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2011 | 237 | 0.020 |
Why?
| Transcriptome | 1 | 2015 | 745 | 0.020 |
Why?
| Molecular Epidemiology | 1 | 2010 | 69 | 0.020 |
Why?
| Metabolome | 1 | 2013 | 283 | 0.020 |
Why?
| Population Groups | 1 | 2010 | 58 | 0.020 |
Why?
| Ki-67 Antigen | 1 | 2010 | 104 | 0.020 |
Why?
| Ligands | 1 | 2011 | 561 | 0.020 |
Why?
| Capillary Permeability | 1 | 2010 | 134 | 0.020 |
Why?
| Drug Combinations | 1 | 2010 | 288 | 0.020 |
Why?
| Australia | 1 | 2010 | 207 | 0.020 |
Why?
| Keratinocytes | 1 | 2010 | 218 | 0.020 |
Why?
| Membrane Proteins | 1 | 2015 | 1032 | 0.020 |
Why?
| NF-kappa B | 2 | 2003 | 634 | 0.020 |
Why?
| Antibodies, Monoclonal | 1 | 2015 | 1259 | 0.020 |
Why?
| Biomarkers | 1 | 2019 | 3450 | 0.020 |
Why?
| Sulfonamides | 1 | 2011 | 446 | 0.020 |
Why?
| Calcium | 1 | 2013 | 1107 | 0.020 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 783 | 0.020 |
Why?
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2007 | 12 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 942 | 0.020 |
Why?
| Verapamil | 1 | 2007 | 32 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2018 | 3070 | 0.020 |
Why?
| Liver Neoplasms | 1 | 2011 | 520 | 0.020 |
Why?
| Blotting, Western | 1 | 2009 | 1146 | 0.020 |
Why?
| Clone Cells | 1 | 2007 | 246 | 0.020 |
Why?
| Calcium Channel Blockers | 1 | 2007 | 114 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2010 | 1855 | 0.020 |
Why?
| Family | 1 | 2010 | 573 | 0.020 |
Why?
| Metabolomics | 1 | 2011 | 530 | 0.020 |
Why?
| Cohort Studies | 1 | 2015 | 4960 | 0.020 |
Why?
| MicroRNAs | 1 | 2012 | 615 | 0.020 |
Why?
| Ovarian Neoplasms | 1 | 2010 | 416 | 0.020 |
Why?
| Adolescent | 2 | 2018 | 17767 | 0.010 |
Why?
| Phosphotransferases | 1 | 2003 | 25 | 0.010 |
Why?
| Young Adult | 1 | 2018 | 10413 | 0.010 |
Why?
| Phentolamine | 1 | 2002 | 16 | 0.010 |
Why?
| Ribosomal Protein S6 Kinases | 1 | 2002 | 21 | 0.010 |
Why?
| Brimonidine Tartrate | 1 | 2002 | 9 | 0.010 |
Why?
| Phenylephrine | 1 | 2002 | 80 | 0.010 |
Why?
| Propranolol | 1 | 2002 | 53 | 0.010 |
Why?
| Peroxidase | 1 | 2002 | 145 | 0.010 |
Why?
| Biological Transport | 1 | 2003 | 375 | 0.010 |
Why?
| Chemokines | 1 | 2003 | 211 | 0.010 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2002 | 145 | 0.010 |
Why?
| Cyclic AMP Response Element-Binding Protein | 1 | 2002 | 127 | 0.010 |
Why?
| Cyclic AMP-Dependent Protein Kinases | 1 | 2002 | 136 | 0.010 |
Why?
| Respiratory Burst | 1 | 2000 | 15 | 0.010 |
Why?
| omega-N-Methylarginine | 1 | 2000 | 23 | 0.010 |
Why?
| MAP Kinase Signaling System | 1 | 2002 | 272 | 0.010 |
Why?
| Inflammation Mediators | 1 | 2003 | 475 | 0.010 |
Why?
| Protein Processing, Post-Translational | 1 | 2002 | 404 | 0.010 |
Why?
| Statistical Distributions | 1 | 1999 | 8 | 0.010 |
Why?
| Matched-Pair Analysis | 1 | 1999 | 35 | 0.010 |
Why?
| Lipopolysaccharides | 1 | 2003 | 822 | 0.010 |
Why?
| Cloning, Molecular | 1 | 2000 | 514 | 0.010 |
Why?
| Intelligence Tests | 1 | 1999 | 59 | 0.010 |
Why?
| Chromosomes, Human | 1 | 1999 | 40 | 0.010 |
Why?
| Nuclear Family | 1 | 1999 | 53 | 0.010 |
Why?
| Hydrogen Peroxide | 1 | 2000 | 286 | 0.010 |
Why?
| Protein-Tyrosine Kinases | 1 | 2002 | 399 | 0.010 |
Why?
| Microsatellite Repeats | 1 | 1999 | 141 | 0.010 |
Why?
| Linkage Disequilibrium | 1 | 1999 | 266 | 0.010 |
Why?
| Models, Genetic | 1 | 1999 | 583 | 0.010 |
Why?
| Cells, Cultured | 1 | 2003 | 3879 | 0.010 |
Why?
| Cytokines | 1 | 2003 | 1837 | 0.010 |
Why?
| Cell Line | 1 | 2000 | 2628 | 0.010 |
Why?
| Molecular Sequence Data | 1 | 1999 | 2773 | 0.010 |
Why?
| Genotype | 1 | 1999 | 1832 | 0.010 |
Why?
| Sex Factors | 1 | 1999 | 1734 | 0.010 |
Why?
| Macrophages | 1 | 2000 | 1273 | 0.010 |
Why?
| Child, Preschool | 1 | 1999 | 9124 | 0.000 |
Why?
| Child | 1 | 1999 | 18435 | 0.000 |
Why?
|
|
Pitts's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|